Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SJP-0132 in dry eye disease
NCT06717152Phase 3Completed
- Sponsor
- Senju Pharmaceutical Co., Ltd.
- Start
- Dec 2024
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dry eye disease (DED) comparing SJP-0132 with Placebo (2 arms). Primary endpoints: Corneal Fluorescein Staining Score at Total Zone at 29 days and Eye Dryness Symptom Visual Analog Scale at 8 days. Started Dec 2024; status: completed.
02
Drugs
motsugibatorep
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT06717152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06717152.